Biogen Reports observational Data for Benralizumab in Rheumatoid arthritis

Biogen today announced observational results for benralizumab in patients with rheumatoid arthritis. The study demonstrated that benralizumab improves functional outcomes compared to standard of care or placebo. These results provide important insights into the treatment of rheumatoid arthritis and support the continued development of benralizumab in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results.